<DOC>
	<DOCNO>NCT01918865</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability , efficacy ISIS-PTP1BRx + oral antidiabetic drug/s ( metformin and/or sulfonylurea ) versus placebo + oral antidiabetic drug/s .</brief_summary>
	<brief_title>Safety , Tolerability , Efficacy ISIS-PTP1BRx Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Body mass index ( BMI ) &gt; /= 27 kg/m2 HbA1c 7.5 % 10.5 % ( inclusive ) CPeptide ( fast ) great equal 500 pmol/L On stable dose metformin alone combination stable dose sulfonylurea &gt; /= 3 month prior screen , remain stable dose throughout study Agree conduct homebased ( fast ) blood glucose test direct Clinically significant abnormality medical history physical exam Serum creatinine &gt; ULN Screening Clinical sign symptoms liver disease , acute chronic hepatitis , ALT AST &gt; 1.5x ULN Screening History renal transplantation renal dialysis GFR &lt; 60 mL/min Screening History diabetic ketoacidosis History great 3 episode severe hypoglycemia within 6 month screen Allergy sulfur contain drug Treatment drug medication allow per study specific Disallowed Concomitant Medicines Any significant illness condition may interfere patient participate complete study Inability unwillingness comply protocol study procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Type 2 Diabetes Mellitus</keyword>
	<keyword>T2DM</keyword>
</DOC>